Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 7
Submit an article Journal homepage
415
Views
1
CrossRef citations to date
0
Altmetric
Letters to Editor

COVID-19 booster vaccines generate seroconversion in subset of patients with lymphoma/CLL: single institution experience

Neha Mehta-Shaha Division of Oncology and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5744-0670View further author information
ORCID Icon,
Nancy L. Bartletta Division of Oncology and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USAORCID Iconhttps://orcid.org/0000-0001-8470-394XView further author information
ORCID Icon,
Brad Kahla Division of Oncology and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USAView further author information
,
Marcus P. Watkinsa Division of Oncology and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USAORCID Iconhttps://orcid.org/0000-0002-1224-3478View further author information
ORCID Icon,
Amalia Duboisa Division of Oncology and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USAView further author information
,
Gabby Schmelzlea Division of Oncology and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USAView further author information
,
Saiama Waqara Division of Oncology and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USAView further author information
,
Claire Ballmanc Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USAView further author information
,
Fei Wanb Department of Surgery, Division of Public Health Sciences, Washington University School of Medicine, St. Louis, MO, USAView further author information
&
Christopher W. Farnsworthc Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USAView further author information
 show all
Pages 1723-1727 | Received 06 Dec 2021, Accepted 30 Jan 2022, Published online: 27 Feb 2022

References

  • Wang Q, Berger NA, Xu R. Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19 infection. JAMA Oncol. 2021;7(2):220–227.
  • Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med. 2020;383(20):1920–1931.
  • Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615.
  • Sadoff J, Le Gars M, Shukarev G, et al. Interim results of a phase 1-2a trial of Ad26.COV2.S covid-19 vaccine. N Engl J Med. 2021;384(19):1824–1835.
  • Herishanu Y, Avivi I, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137(23):3165–3173.
  • Greenberger LM, Saltzman LA, Senefeld JW, et al. Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies. Cancer Cell. 2021;39(10):1297–1299.
  • Jurgens EM, Ketas TJ, Zhao Z, et al. Serologic response to mRNA COVID-19 vaccination in lymphoma patients. Am J Hematol. 2021;96(11):E410–E413.
  • Greenberger LM, Saltzman LA, Senefeld JW, et al. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. Cancer Cell. 2021;39(8):1031–1033.
  • Administration U. EUA 26382: Emergency Use Authorization (EUA) for the emergency use of COVID-19 convalescent plasma (3-9-2021 Amendment); 2021.
  • Administration U. EUA 26382: Emergency Use Authorization (EUA) Request for COVID-19 Convalescent Plasma; 2020.
  • Ebinger JE, Fert-Bober J, Printsev I, et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med. 2021;27(6):981–984.
  • Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med. 2021;385(16):1474–1484.
  • Benotmane I, Gautier G, Perrin P, et al. Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses. JAMA. 2021;326(11):1063–1065.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.